For the second quarter Eli Lilly on a July 23 earnings call heard John Lechleiter, chairman, president and CEO, and his team provided upbeat talk about opportunities in Japan. But there was also some of the same comments heard from Johnson & Johnson, Abbott and Novartis on China's slowdown.
For the second quarter Roche on a July 23 earnings call saw CEO Severin Schwan speak about the cancer immunotherapy pipeline at some length, but his two chief operating officers provided details on emerging markets.
Last week, China approved the rollout of medical insurance on serious illness nationwide, said Liang Wannian, vice-director of the medical reform office under the State Council and a senior official with China's National Health and Family Planning Commission, at a July 24 policy briefing.
Hong Kong-listed 3SBio made its second big move in as many months since it came back onto the market, buying small molecule maker Zhejiang Wansheng Pharma for $85 million.
Hong Kong-based Hutchison China MediTech has cemented its already majority stake in in Hutchison MediPharma via a share exchange deal with Japan's Mitsui & Co. in a disclosure notice with few details, but ahead of study results later this year on a promising candidate for China approval.
FiercePharmaAsia combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.
China's Shandong Freda Pharmaceutical Group has obtained a license to sell direct to consumers, China Daily reports, highlighting a trend that has gathered pace across over-the-counter and healthcare products as companies also eye Beijing for a nod on ethical drugs.
Calgary-based Resverlogix said it has closed a deal to license greater China rights to clinical stage cardiovascular drug RVX-208 to China's Shenzhen Hepalink Pharmaceutical, putting its future on an known candidate now billed as a new treatment for atherosclerosis.
China healthcare policymakers are fighting a losing battle to curb the growth of public urban "superhospitals" that now see expansion as more important than ever to survival in the face of a move in May to scrap a 15% markup on drug prescriptions, Reuters reports.
For the second quarter of the year, Johnson & Johnson as usual has the pole position on reporting, and CEO Alex Gorsky was on hand with a midyear update.